Stock Events

Evelo Biosciences 

$0
21
+$0+0% Friday 19:15

Statistics

Day High
0
Day Low
0
52W High
13.93
52W Low
0
Volume
6,294
Avg. Volume
25,132
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

14MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-3.78
-2.58
-1.39
-0.19
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EVLO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap14.34B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, competing in the biotech space with novel treatments similar to Evelo's approach.
Vertex Pharmaceuticals
VRTX
Mkt Cap122.46B
Vertex Pharmaceuticals is involved in creating transformative medicines for serious diseases, directly competing with Evelo's mission in the biotech industry.
Regeneron Pharmaceuticals
REGN
Mkt Cap111.64B
Regeneron Pharmaceuticals specializes in developing medications for rare and severe conditions, aligning as a competitor in the biotech field against Evelo.
Biogen
BIIB
Mkt Cap32.85B
Biogen focuses on neurology and rare diseases, competing with Evelo Biosciences in the development of innovative biotechnological treatments.
AMGEN
AMGN
Mkt Cap166.77B
Amgen is a biotech firm that develops a wide range of therapeutic products, potentially competing with Evelo's product pipeline.
Gilead Sciences
GILD
Mkt Cap83.09B
Gilead Sciences is known for its work in antiviral drugs and other areas of high unmet medical need, positioning it as a competitor to Evelo.
CRISPR Therapeutics
CRSP
Mkt Cap4.51B
CRISPR Therapeutics is at the forefront of gene editing, a technology that could compete with Evelo's microbiome-based therapies.
Novartis
NVS
Mkt Cap236.8B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments in areas where Evelo Biosciences may also be aiming to innovate.
Moderna
MRNA
Mkt Cap45.34B
Moderna is known for its mRNA technology platform, competing in the innovative treatment space, including potential overlaps with Evelo's focus areas.

About

Health Technology
Pharmaceuticals: Major
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Employees
66
Country
US
ISIN
US2997341035

Listings